280 related articles for article (PubMed ID: 35400564)
1. Tenascin-C in fibrosis in multiple organs: Translational implications.
Bhattacharyya S; Midwood KS; Varga J
Semin Cell Dev Biol; 2022 Aug; 128():130-136. PubMed ID: 35400564
[TBL] [Abstract][Full Text] [Related]
2. Endogenous ligands of TLR4 promote unresolving tissue fibrosis: Implications for systemic sclerosis and its targeted therapy.
Bhattacharyya S; Varga J
Immunol Lett; 2018 Mar; 195():9-17. PubMed ID: 28964818
[TBL] [Abstract][Full Text] [Related]
3. Tenascin-C drives persistence of organ fibrosis.
Bhattacharyya S; Wang W; Morales-Nebreda L; Feng G; Wu M; Zhou X; Lafyatis R; Lee J; Hinchcliff M; Feghali-Bostwick C; Lakota K; Budinger GR; Raparia K; Tamaki Z; Varga J
Nat Commun; 2016 Jun; 7():11703. PubMed ID: 27256716
[TBL] [Abstract][Full Text] [Related]
4. TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung.
Bhattacharyya S; Wang W; Qin W; Cheng K; Coulup S; Chavez S; Jiang S; Raparia K; De Almeida LMV; Stehlik C; Tamaki Z; Yin H; Varga J
JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997297
[TBL] [Abstract][Full Text] [Related]
5. Emerging roles of innate immune signaling and toll-like receptors in fibrosis and systemic sclerosis.
Bhattacharyya S; Varga J
Curr Rheumatol Rep; 2015 Jan; 17(1):474. PubMed ID: 25604573
[TBL] [Abstract][Full Text] [Related]
6. Extracellular Matrix-Derived Damage-Associated Molecular Patterns (DAMP): Implications in Systemic Sclerosis and Fibrosis.
Bale S; Verma P; Varga J; Bhattacharyya S
J Invest Dermatol; 2023 Oct; 143(10):1877-1885. PubMed ID: 37452808
[TBL] [Abstract][Full Text] [Related]
7. The Role of Pro-fibrotic Myofibroblasts in Systemic Sclerosis: From Origin to Therapeutic Targeting.
Romano E; Rosa I; Fioretto BS; Matucci-Cerinic M; Manetti M
Curr Mol Med; 2022; 22(3):209-239. PubMed ID: 33823766
[TBL] [Abstract][Full Text] [Related]
8. Deficiency of inhibitory TLR4 homolog RP105 exacerbates fibrosis.
Wang W; Bale S; Yalavarthi B; Verma P; Tsou PS; Calderone KM; Bhattacharyya D; Fisher GJ; Varga J; Bhattacharyya S
JCI Insight; 2022 Nov; 7(21):. PubMed ID: 36136452
[TBL] [Abstract][Full Text] [Related]
9. FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling.
Bhattacharyya S; Tamaki Z; Wang W; Hinchcliff M; Hoover P; Getsios S; White ES; Varga J
Sci Transl Med; 2014 Apr; 6(232):232ra50. PubMed ID: 24739758
[TBL] [Abstract][Full Text] [Related]
10. Toll-Like Receptor-4 Signaling Drives Persistent Fibroblast Activation and Prevents Fibrosis Resolution in Scleroderma.
Bhattacharyya S; Midwood KS; Yin H; Varga J
Adv Wound Care (New Rochelle); 2017 Oct; 6(10):356-369. PubMed ID: 29062592
[No Abstract] [Full Text] [Related]
11. Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease.
Valenzi E; Bulik M; Tabib T; Morse C; Sembrat J; Trejo Bittar H; Rojas M; Lafyatis R
Ann Rheum Dis; 2019 Oct; 78(10):1379-1387. PubMed ID: 31405848
[TBL] [Abstract][Full Text] [Related]
12. A Human Skin Model Recapitulates Systemic Sclerosis Dermal Fibrosis and Identifies COL22A1 as a TGFβ Early Response Gene that Mediates Fibroblast to Myofibroblast Transition.
Watanabe T; Baker Frost DA; Mlakar L; Heywood J; da Silveira WA; Hardiman G; Feghali-Bostwick C
Genes (Basel); 2019 Jan; 10(2):. PubMed ID: 30678304
[No Abstract] [Full Text] [Related]
13. Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis.
Korman B
Transl Res; 2019 Jul; 209():77-89. PubMed ID: 30876809
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis.
Bhattacharyya S; Wang W; Tamaki Z; Shi B; Yeldandi A; Tsukimi Y; Yamasaki M; Varga J
Front Immunol; 2018; 9():2434. PubMed ID: 30405628
[TBL] [Abstract][Full Text] [Related]
15. Toll-like Receptor 9 Signaling Is Augmented in Systemic Sclerosis and Elicits Transforming Growth Factor β-Dependent Fibroblast Activation.
Fang F; Marangoni RG; Zhou X; Yang Y; Ye B; Shangguang A; Qin W; Wang W; Bhattacharyya S; Wei J; Tourtellotte WG; Varga J
Arthritis Rheumatol; 2016 Aug; 68(8):1989-2002. PubMed ID: 26946325
[TBL] [Abstract][Full Text] [Related]
16. Reduced SPAG17 Expression in Systemic Sclerosis Triggers Myofibroblast Transition and Drives Fibrosis.
Sapao P; Roberson EDO; Shi B; Assassi S; Skaug B; Lee F; Naba A; Perez White BE; Córdova-Fletes C; Tsou PS; Sawalha AH; Gudjonsson JE; Ma F; Verma P; Bhattacharyya D; Carns M; Strauss JF; Sicard D; Tschumperlin DJ; Champer MI; Campagnola PJ; Teves ME; Varga J
J Invest Dermatol; 2023 Feb; 143(2):284-293. PubMed ID: 36116512
[TBL] [Abstract][Full Text] [Related]
17. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?
Jimenez SA; Piera-Velazquez S
Matrix Biol; 2016 Apr; 51():26-36. PubMed ID: 26807760
[TBL] [Abstract][Full Text] [Related]
18. The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis.
Artlett CM; Sassi-Gaha S; Rieger JL; Boesteanu AC; Feghali-Bostwick CA; Katsikis PD
Arthritis Rheum; 2011 Nov; 63(11):3563-74. PubMed ID: 21792841
[TBL] [Abstract][Full Text] [Related]
19. Egr-1: new conductor for the tissue repair orchestra directs harmony (regeneration) or cacophony (fibrosis).
Bhattacharyya S; Fang F; Tourtellotte W; Varga J
J Pathol; 2013 Jan; 229(2):286-97. PubMed ID: 23132749
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
